Grabar Law Office is investigating claims on behalf of shareholders of 3D Systems Corporation (NYSE: DDD). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

3D Systems provides 3D printing and digital manufacturing solutions in North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The Company earns revenue from the sale of products and services through its two operating segments: Healthcare Solutions and Industrial Solutions. The Healthcare Solutions segment includes dental, medical devices, personalized health services, and regenerative medicine (the “Regenerative Medicine Program”).

As alleged in a recently filed securities fraud class action complaint, 3D Systems (NYSE: DDD), via certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions; (ii) in addition, the updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT YOU CAN DO NOW: If you purchased 3D Systems Corporation (NYSE: DDD) shares prior to August 13, 2024, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.